-
PTC Therapeutics Could Quintuple In Price, Oppenheimer Predicts
Monday, October 5, 2015 - 3:02pm | 335Shares of PTC Therapeutics, Inc. (NASDAQ: PTCT) lost nearly 8 percent by Monday afternoon. The company released Phase 2 data at the International Congress of the World Muscle Society. Christopher Marai of Oppenheimer maintained an Outperform rating and unchanged $155 price target...